In light of the advent of immunotherapy for the treatment of NSCLC, there is an increasing knowledge about the limited efficacy of PD‐1/PD‐L1 inhibitors in patients with EGFR‐mutant NSCLC.15, 23, 24, 25. Here, EGFR is linked to non-small cell lung carcinoma.